Antidepressants (Migraine) - Forecast and Market Analysis to 2023

News provided by

May 21, 2014, 11:53 ET

NEW YORK, May 21, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antidepressants (Migraine) - Forecast and Market Analysis to 2023

http://www.reportlinker.com/p02114398/Antidepressants-Migraine---Forecast-and-Market-Analysis-to-2023.html

Summary

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

Certain Antidepressants have been used for the treatment of migraine since the 1970s (Gomersall and Stuart, 1973). Several classes of antidepressants exist, each with a different mechanism of action. These include tricyclic antidepressants (TCAs), MAO inhibitors, selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs). Although the mechanism by which antidepressants prevent migraine headache is unknown, improvement is independent from treating masked depression; the response occurs sooner than the antidepressive effect.

Scope

- Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Antidepressants including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Antidepressants for the top five countries from 2012 to 2023.
- Sales information covered for the US, France, Italy, Spain and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Migraine
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Antidepressants performance
- Obtain sales forecast for Antidepressants from 2012-2023 in the top five countries (the US, France, Italy, Spain and Japan)
1 Table of Contents

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 15
3.1.3 Prognosis 16
3.2 Symptoms 16
3.2.1 Premonitory Phase 17
3.2.2 Aura Phase 17
3.2.3 Headache Phase 18
3.2.4 Postdrome Phase 18
4 Disease Management 19
4.1 Treatment Overview 19
4.1.1 Acute Migraine Treatment 22
4.1.2 Preventive Migraine Treatment 23
5 Competitive Assessment 24
5.1 Overview 24
5.2 Strategic Competitor Assessment 25
6 Antidepressants 26
6.1 Overview 26
6.2 Efficacy 27
6.3 Safety 28
6.4 SWOT Analysis 28
6.5 Forecast 28
7 Appendix 30
7.1 Bibliography 30
7.2 Abbreviations 33
7.3 Methodology 34
7.4 Forecasting Methodology 34
7.4.1 Diagnosed Migraine Patients 35
7.4.2 Percent Drug-treated Patients 35
7.4.3 General Pricing Assumptions 35
7.4.4 Individual Drug Assumptions 36
7.4.5 Generic Erosion 36
7.5 Physicians and Specialists Included in this Study 37
7.6 Survey of Prescribing Physicians 38
7.7 About the Authors 39
7.7.1 Author 39
7.7.2 Reviewer 39
7.7.3 Global Head of Healthcare 40
7.8 About GlobalData 41
7.9 Disclaimer 41

1.1 List of Tables

Table 1: Classification of Migraine Subtypes 13
Table 2: Diagnostic Criteria for Migraine with Aura 17
Table 3: Diagnostic Criteria for Migraine without Aura 18
Table 4: Treatment Guidelines for Migraine 20
Table 5: Most Prescribed Drugs for Migraine by Class in the Major Markets, 2013 21
Table 6: Product Profile - Antidepressants 27
Table 7: Antidepressants SWOT Analysis, 2013 28
Table 8: Global Sales Forecasts ($m) for Antidepressants, 2012-2023 29
Table 9: Physicians Surveyed, By Country 38

1.2 List of Figures

Figure 1: Migraine Treatment Algorithm in the 7MM 21

To order this report: Antidepressants (Migraine) - Forecast and Market Analysis to 2023
http://www.reportlinker.com/p02114398/Antidepressants-Migraine---Forecast-and-Market-Analysis-to-2023.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker